India’s biggest companies are no longer just executing; they are innovating. From electric vehicles to life-saving drugs and cutting-edge defense systems, the latest insights reveal that India's biggest R&D expenditures are being made on cars, drugs, and defense.
Here is a breakdown of who is spending the most, and what this massive investment means for the future of the Indian economy.
The Top R&D Spenders in FY26
According to the data, these are the 10 Indian companies with the highest absolute R&D expenditures for the fiscal year:
1. Mahindra & Mahindra: ₹5,691 Cr. (3.9% of turnover)
2. Reliance Industries: ₹4,682 Cr. (0.9% of turnover)
3. Tata Motors (PV): ₹2,836 Cr. (3.8% of turnover)
4. Hindustan Aeronautics: ₹2,794 Cr. (8.8% of turnover)
5. Dr. Reddy’s Laboratories: ₹2,157 Cr. (10.5% of turnover)
6. Sun Pharmaceutical: ₹2,142 Cr. (10.3% of turnover)
7. Bharat Electronics: ₹1,961 Cr. (7.7% of turnover)
8. Tata Motors: ₹1,690 Cr. (2.2% of turnover)
9. Cipla: ₹1,618 Cr. (8.5% of turnover)
10. Zydus Lifesciences: ₹1,384 Cr. (12.1% of turnover)
(Note: Figures are based on standalone financial statements)
The Three Pillars of Indian Innovation
Looking at the data, the spending is heavily concentrated in three critical sectors:
1. Automobile & The EV Revolution
Auto companies are aggressively investing in the future of mobility—battery technology, EV platforms, software, and advanced safety systems. Mahindra & Mahindra is leading the charge as the biggest R&D spender in FY26, pouring ₹5,691 crore into innovation (up 81% from last year). This investment is clearly paying off. In FY26, M&M captured a massive 37.4% revenue share of India’s electric SUV market. Tata Motors (both the Passenger Vehicle and overall entity) also remains a heavyweight, spending billions to solidify its position as an early mover in the Indian EV space.
2. Pharmaceuticals: The High-Risk, High-Reward Game
In the pharma space, you cannot cut corners. Bringing a new drug to market requires years of rigorous research, clinical testing, and regulatory approvals. This is why pharma companies spend a much larger share of their revenue on R&D compared to other sectors. Dr. Reddy's Laboratories (10.5%), Sun Pharmaceutical (10.3%), Cipla (8.5%), and Zydus Lifesciences (12.1%) all allocated over 10% (or close to it) of their turnover toward R&D in FY26. This relentless focus on innovation is what allows Indian pharma to compete globally and secure lucrative patents.
3. Defense & Aerospace: Building for Security
With a renewed global focus on national security and the "Make in India" initiative, defense companies are investing heavily in indigenous technology. Hindustan Aeronautics (HAL) spent ₹2,794 crore (8.8% of turnover) and Bharat Electronics spent ₹1,961 crore (7.7% of turnover). These investments are crucial for developing next-generation fighter jets, radar systems, and advanced electronic warfare capabilities.
The Reliance Anomaly
At first glance, Reliance Industries looks like a massive spender at ₹4,682 crore. However, this represents only 0.9% of its turnover. This highlights the sheer, colossal scale of Reliance's overall operations. While they are investing billions in green energy, retail tech, and telecom (Jio), their massive revenue base keeps the percentage relatively low.
The Investor Takeaway
For retail investors, R&D spending is a crucial metric to track. It is the clearest indicator of a company's long-term vision.
Companies that sacrifice short-term profits to invest heavily in R&D are usually building an economic "moat" that protects them from future competition. Whether it's Mahindra's bet on EVs or Zydus's bet on new drugs, these investments are the seeds of future earnings growth.
As India transitions from a consumption-driven economy to an innovation-driven one, the companies on this list are the ones most likely to lead the next decade of growth.